Acura Pharmaceuticals Inc.
03/10/2026 | Press release | Distributed by Public on 03/10/2026 14:36
Material Agreement, Asset Transaction, Financial Obligation (Form 8-K)
Amended Loan Schedule to Secured Promissory Note dated November 10, 2022
between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC
| Date | Principal |
Aggregated Principal |
||||||||||
| Original Secured Promissory Note | 11/10/2022 | $ | 2,319,279 | $ | 2,319,279 | |||||||
| Additional Loans to be included: | ||||||||||||
| Loans #1 dated 12/22/2022 through Loans #50 dated 12/31/2025 | $ | 7,075,000 | $ | 9,394,279 | ||||||||
| Loan #51 | 1/02/2026 | $ | 100,000 | $ | 9,494,279 | |||||||
| Loan #52 | 1/16/2026 | $ | 100,000 | $ | 9,594,279 | |||||||
| Loan #53 | 2/06/2026 | $ | 100,000 | $ | 9,694,279 | |||||||
| Loan #54 | 2/13/2026 | $ | 100,000 | $ | 9,794,279 | |||||||
| Loan #55 | 3/09/2026 | $ | 100,000 | $ | 9,894,279 | |||||||
ACURA PHARMACEUTICALS, INC.
| By: | /s/ Robert A. Seiser | |
| Robert A. Seiser | ||
| Senior Vice President & CFO | ||
| Date: March 9, 2026 | ||
Acura Pharmaceuticals Inc. published this content on March 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 10, 2026 at 20:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]